Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization
- PMID: 3898484
- DOI: 10.1016/0035-9203(85)90388-8
Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization
Abstract
The efficacy of passive immunization for treatment of Lassa Fever (LF) is believed to depend on the titre of the neutralizing antibody infused. For the purpose of identifying optimal donors of LV-immune plasma, a population of LF-convalescent patients in Liberia was tested for prevalence of neutralizing antibody. Minimally protective titres, expressed as a log10 neutralization index, (LNI), were established in animal models as LNI greater than 2. LNI titres for 26 donors, tested eight or more months after illness, were modest: 16 titred 1 less than LNI less than 2, 4 titred 2 greater than LNI less than 3, and only 4 titred LNI greater than 3. Sequentially obtained plasma from six donors indicated that the LNI response was delayed relative to the indirect fluorescent antibody (IFA) response, that high titres (LNI greater than 3) occurred only after seven months and in only two of six patients. Most of the unselected LV-immune plasma will require concentration to therapeutically useful LNI titres. In a passive immunization experiment, guinea-pigs were protected by a late convalescent plasma (LNI = 4.8, IFA = 320) but not by an early plasma, (LNI = 0.6, IFA = 640), thus supporting the selection of immune plasma on the basis of the LNI. Cross serological testing with LV strains and convalescent plasma from patients in Sierra Leone, Liberia and Nigeria suggested that these LV strains were indistinguishable by cross-IFA, but were readily distinguishable by cross neutralization tests. Geographical matching of LV and plasma origins may thus be a factor in selection of optimal plasma for passive immunization of Lassa fever.
Similar articles
-
Protection of Lassa virus-infected guinea pigs with Lassa-immune plasma of guinea pig, primate, and human origin.J Med Virol. 1983;12(2):93-102. doi: 10.1002/jmv.1890120203. J Med Virol. 1983. PMID: 6619814
-
Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain.Infect Immun. 1984 May;44(2):528-33. doi: 10.1128/iai.44.2.528-533.1984. Infect Immun. 1984. PMID: 6715049 Free PMC article.
-
Endemic Lassa fever in Liberia. III. Characterization of Lassa virus isolates.Trans R Soc Trop Med Hyg. 1985;79(3):374-9. doi: 10.1016/0035-9203(85)90386-4. Trans R Soc Trop Med Hyg. 1985. PMID: 3898483
-
Antibody therapy for Lassa fever.Curr Opin Virol. 2019 Aug;37:97-104. doi: 10.1016/j.coviro.2019.07.003. Epub 2019 Aug 8. Curr Opin Virol. 2019. PMID: 31401518 Review.
-
Immunobiology of Ebola and Lassa virus infections.Nat Rev Immunol. 2017 Mar;17(3):195-207. doi: 10.1038/nri.2016.138. Epub 2017 Jan 23. Nat Rev Immunol. 2017. PMID: 28111475 Review.
Cited by
-
Lassa Virus Treatment Options.Microorganisms. 2021 Apr 7;9(4):772. doi: 10.3390/microorganisms9040772. Microorganisms. 2021. PMID: 33917071 Free PMC article. Review.
-
Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease.Proc Natl Acad Sci U S A. 2012 Mar 27;109(13):5034-9. doi: 10.1073/pnas.1200409109. Epub 2012 Mar 12. Proc Natl Acad Sci U S A. 2012. PMID: 22411795 Free PMC article.
-
Mice lacking functional STAT1 are highly susceptible to lethal infection with Lassa virus.J Virol. 2013 Oct;87(19):10908-11. doi: 10.1128/JVI.01433-13. Epub 2013 Jul 31. J Virol. 2013. PMID: 23903830 Free PMC article.
-
Improving the Breadth of the Host's Immune Response to Lassa Virus.Pathogens. 2018 Oct 28;7(4):84. doi: 10.3390/pathogens7040084. Pathogens. 2018. PMID: 30373278 Free PMC article. Review.
-
Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development.NPJ Vaccines. 2018 Mar 20;3:11. doi: 10.1038/s41541-018-0049-5. eCollection 2018. NPJ Vaccines. 2018. PMID: 29581897 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources